Anika Therapeutics, Inc., a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology, announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is indicated for filling bone voids or defects of the skeletal system (i.e., extremities and pelvis), which are…